Figure
Frederick Banting became one of the best-known figures in the history of diabetes because of the Toronto work that turned pancreatic extracts into usable insulin therapy. His name is tied to discovery, but also to teamwork, laboratory conflict, clinical testing, and the rapid movement from experiment to life-saving treatment.
Banting matters because insulin changed diabetes from an often fatal diagnosis into a chronic condition that could be managed, provided patients had access to a dependable medical and industrial system.
Major Contributions
Banting's work with Charles Best in J.J.R. Macleod's laboratory focused on pancreatic extracts that could lower blood sugar. The research drew on earlier physiology, but it became historically powerful when it moved toward clinical use.
The insulin therapy milestone became a dramatic example of modern biomedical success: laboratory experiment, hospital testing, purification, production, and patient survival working together.
Banting shared the story with Best, Macleod, Collip, Leonard Thompson, and earlier diabetes researchers. The disputes over credit show that modern medical discovery is rarely the work of one person alone.
Historical Context
Researchers had already connected diabetes to the pancreas and the islets of Langerhans, and several groups had attempted to prepare pancreatic extracts. In 1920 Banting formed a new experimental proposal after reading about pancreatic ducts. He brought it to University of Toronto physiology professor J. J. R. Macleod, who supplied laboratory space, animals, advice, and the assistance of student Charles Best in the summer of 1921.
Early extracts lowered blood glucose in depancreatised dogs, but turning that effect into treatment required more reliable preparation. Biochemist James Collip joined the group and improved purification. At Toronto General Hospital, fourteen-year-old Leonard Thompson received an initial extract in January 1922; a more purified preparation then produced clear clinical improvement without the severe reaction caused by the first injection.
Demand immediately exceeded the university team's production capacity. Connaught Laboratories and pharmaceutical manufacturers helped develop larger batches, quality controls, and distribution. Banting, Best, and Collip assigned their patent rights to the University of Toronto for a nominal payment, hoping institutional oversight would protect the therapy.
A continuing therapy
Insulin did not cure diabetes. Patients and families had to coordinate injections, food, symptoms, monitoring, clinical appointments, and the risk of dangerously low blood sugar.
Banting's difficult relationships with Macleod and Collip shaped the public memory of discovery. The dispute shows how prizes and heroic biographies can obscure the different expertise required to make a therapy work.
Survival depended on dependable manufacturing, refrigeration, clinical knowledge, and affordability. The history of insulin therefore continues in present arguments about patents, markets, public investment, and unequal access.
Reading Path
Read this profile with History of Diabetes and Insulin, Insulin Therapy, 1921, and History of Medical Education to see how laboratory medicine, clinical institutions, and therapeutic production reshaped twentieth-century care.